Aphria Inc. (OTCMKTS:APHQF) has acquired a license amendment from Health Canada that offers it with added production region of 57,000 square feet. This is completed as part of firm’s Part 2 extension at its Leamington facility. This will virtually triple firm’s production capacity of therapeutic cannabis to 8,000 kgs yearly from 2,600 kgs yearly.
The Health Canada authorization revision is a part of the “ACMPR” process. Aphria posted that the first crop produced and cultivated at the Part II new area will be accessible for sale in the next two months. Vic Neufeld, who is the CEO, posted that the license amendment registers the conclusion of the next stage of firm’s four-part expansion plan, set to be closed by July 2018.
This will permit them to continue to produce high-quality cannabis at premium prices in the industry. The growth will support greenhouse mark of firm to become the biggest in the market and attain long-term strategic plan.
Aphria is included in the list of lowest cost Canadian producers that produces, supplies and sells therapeutic cannabis. Based in Leamington, the firm has all the natural conditions set to support cannabis production. The firm intends to provide pharma-grade therapeutic cannabis, best patient care while corresponding patient economics and yields to stockholders.
Aphria became the primary public licensed company to register positive cash flow generated from its cannabis activities. It is also the first cannabis firm to post positive fiscal revenue in sequential quarters.
The firm has released its Seed to Sale permitted quality promise so as to develop its plans of grow and manufacturing of safe and clean therapeutic cannabis.
In the previous trading session, the shares of Aphria declined more than 3% to close the day at $4.06. The drop came at a share volume of 168,347 compared to average share volume of 272,489.
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies
Can CBD Oil Get Rid of Chronic Pain?http://www.greenleaf.farm
Pure Colorado Golden CBD Oil Hemp Extracts
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure